Home
Products
Learn
About
Pricing
Log In
Back
PERAO

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

๐Ÿ‡ฆ๐Ÿ‡บ ASX

๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿƒ Esg

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

N/A
Annual Growth

5 years average annual capital growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

4
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

Percheron Therapeutics Limited - Option Expiring 20-May-2028 Deferred

๐Ÿ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

empty share chartempty share line

Performance graph isn't available yet for this share

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in PERAO

4

๐Ÿ“Š Total Capital Earnings

N/A

๐Ÿ”ƒ Average investment frequency

N/A

๐Ÿ’ต Average investment amount

N/A

โฐ Last time a customer invested in PERAO

N/A
PERAO investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

50%

50k - 100k

Less than 50k

50%
๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

25%

35 - 90

75%
๐Ÿ™‹ Legal gender of investors

Female

Male

100%

Pearlers who invest in PERAO also invest in...

Percheron Therapeutics Limited

PER

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Companyโ€™s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.

๐Ÿ™Œ Performance (5Yr p.a)

-17.14%

๐Ÿ“Š Share price

$0.01 AUD

๐Ÿ“ฆ LOGISTICS

Find Out More

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

๐Ÿ™Œ Performance (5Yr p.a)

20.30%

๐Ÿ“Š Share price

$49.75 AUD

๐Ÿ“ˆ HIGH PRICE GROWTH

๐Ÿค– TECHNOLOGY

๐Ÿ‡บ๐Ÿ‡ธ UNITED STATES

RBTZ.AX was created on 2018-09-12 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. ๏ปฟRBTZ.AX aims to track the performance of an index (before fees and expenses) that includes global companies involved in the production or use of robotics and artificial intelligence (A.l.) products and services.

๐Ÿ™Œ Performance (5Yr p.a)

4.32%

๐Ÿ“Š Share price

$13.69 AUD

๐Ÿค– TECHNOLOGY

๐Ÿ‡ฆ๐Ÿ‡บ EX AUSTRALIA

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

15.99%

๐Ÿ“Š Share price

$139.40 AUD

๐ŸŒ GLOBAL

๐Ÿค– TECHNOLOGY

โ›ณ๏ธ DIVERSIFIED

๐Ÿ“ˆ HIGH PRICE GROWTH

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as โ€œClimate Leadersโ€ that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

๐Ÿ™Œ Performance (5Yr p.a)

8.97%

๐Ÿ“Š Share price

$15.47 AUD

๐ŸŒ GLOBAL

๐Ÿค– TECHNOLOGY

โ›ณ๏ธ DIVERSIFIED

๐Ÿ“ˆ HIGH PRICE GROWTH

Want more shares? Try these...

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Companyโ€™s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.

๐Ÿ™Œ Performance (5Yr p.a)

-17.14%

๐Ÿ“Š Share price

$0.01 AUD

๐Ÿ“ฆ LOGISTICS